{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:03:03Z","timestamp":1793156583017,"version":"4.5.0"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a previous paper, a comprehensive clinicopathologic approach to mild and moderate bleeding disorders (MBD) was proposed by an international working group (IWG) as a part of a project promoted by the European Hematology Association (EHA) on the development of guidelines on the various MBDs. A single pre\u2010diagnosis grade 4 bleeding event according to the ISTH\u2010BAT scale or a comparable event after diagnosis was considered sufficient to classify a patient as affected by a severe bleeding disorder (SBD). In this article, the original IWG integrated by experts and patients' representatives proposed by the European Haemophilia Consortium (EHC) and European Association of Haemophilia and Allied Disorders (EAHAD) applied these criteria to mild and moderate hemophilia A and B to establish the proportion of cases that would be reclassified as SBD taking into account bleeding phenotype, thus improving over the current classification based exclusively on basal factor VIII or IX level. To this aim, publications of unselected cases with bleeding history available from birth to the time of publication were considered to estimate the incidence of a first severe bleeding event. More than 20% of cases with mild or moderate hemophilia met the criteria for SBD by experiencing joint or non\u2010joint severe bleeding events. Furthermore, a significant proportion of patients developed an inhibitor against factor VIII or IX. These results, based on a rigorous methodologic approach, substantiate the criticism of the current classification of hemophilia and argue for the adoption of a new classification that takes into account bleeding phenotype in addition to basal clotting activity.<\/jats:p>","DOI":"10.1002\/hem3.70111","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:55:00Z","timestamp":1743116100000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2253-2502","authenticated-orcid":false,"given":"Francesco","family":"Rodeghiero","sequence":"first","affiliation":[{"name":"Hematology Project Foundation, Affiliated to the Department of Hematology San Bortolo Hospital Vicenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6438-7810","authenticated-orcid":false,"given":"Lisanna","family":"Ghiotto","sequence":"additional","affiliation":[{"name":"Hematology Project Foundation, Affiliated to the Department of Hematology San Bortolo Hospital Vicenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pontalto","sequence":"additional","affiliation":[{"name":"Hematology Project Foundation, Affiliated to the Department of Hematology San Bortolo Hospital Vicenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Casini","sequence":"additional","affiliation":[{"name":"Division of Angiology and Hemostasis, Department of Medicine, University Hospitals of Geneva University of Geneva Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Center for Bleeding Disorders and Coagulation Careggi University Hospital Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezan","family":"Abdul\u2010Kadir","sequence":"additional","affiliation":[{"name":"The Royal Free NHS Foundation Hospital, Institute for Women's Health University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Lund University Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Bod\u00f3","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology Semmelweis University Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Degenaar\u2010Dujardin","sequence":"additional","affiliation":[{"name":"European Haemophilia Consortium Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center University of Amsterdam Amsterdam The Netherlands"},{"name":"Department of Molecular Cellular Hemostasis Sanquin Research and Landsteiner Laboratory Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gresele","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine University of Perugia Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, UNC Blood Research Center University of North Carolina School of Medicine Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[{"name":"Coagulation Disorders Unit, Division of Hematology, Department of Medicine Helsinki University Central Hospital, Finland Wihuri Research Institute Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine Queen's University Kingston Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Makris","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health University of Sheffield Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Meijer","sequence":"additional","affiliation":[{"name":"Nederlandse Vereniging van Hypothecair Planners (NVHP) \u2013 for everyone with a congenital bleeding disorder Nijkerk The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Mezzano","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2013Oncology, School of Medicine Pontificia Universidad Cat\u00f3lica de Chile Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Noris","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Pavia Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"Clinical Division of Haematology and Haemostaseology, Department of Medicine I Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology University of Pittsburgh Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Silva","sequence":"additional","affiliation":[{"name":"Spanish Federation of Hemophilia, \u201cVictoria Eugenia\u201d Royal Foundation Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Hematology Christian Medical College Hospital Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-5204","authenticated-orcid":false,"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[{"name":"Department of Hematology San Bortolo Hospital Vicenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Windyga","sequence":"additional","affiliation":[{"name":"Department of Hemostasis Disorders and Internal Medicine Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Zieger","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, University Medical Centre Freiburg University of Freiburg Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"4","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000286","article-title":"Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA consensus report","volume":"3","author":"Rodeghiero F","year":"2019","journal-title":"HemaSphere"},{"issue":"1","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ijlh.14266","article-title":"How to investigate mild to moderate bleeding disorders and bleeding disorder of unknown cause","volume":"46","author":"Casini A","year":"2024","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White G","year":"2001","journal-title":"Thromb Haemost"},{"issue":"7","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jtha.2023.03.016","article-title":"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets","volume":"21","author":"Thachil J","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"10","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.jtha.2023.07.026","article-title":"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets\u201d: comment","volume":"21","author":"Gorman R","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"10","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.jtha.2023.07.029","article-title":"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets\u201d: reply","volume":"21","author":"Thachil J","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"3","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open\u2010label, single\u2010arm, phase 3 study","volume":"10","author":"N\u00e9grier C","year":"2023","journal-title":"Lancet Haematol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"e_1_2_10_10_1","first-page":"337","article-title":"A biological standard for measurement of blood coagulation Factor VIII activity","volume":"45","author":"Bangham DR","year":"1971","journal-title":"Bull World Health Organ"},{"issue":"2","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1600-0609.1970.tb01873.x","article-title":"Another genetic variant of haemophilia B: haemophilia B Leyden","volume":"7","author":"Veltkamp JJ","year":"1970","journal-title":"Scand J Haematol"},{"issue":"9","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero F","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"11","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/j.1538-7836.2008.03126.x","article-title":"Less severe bleeding in hemophilia B than in hemophilia A","volume":"6","author":"Lowe GDO","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"1","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2141.1958.tb03830.x","article-title":"Haemophilia and related conditions: a survey of 187 cases","volume":"4","author":"Biggs R","year":"1958","journal-title":"Br J Haematol"},{"issue":"11","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette VS","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"08","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1055\/s-0035-1564800","article-title":"Definitions in hemophilia: resolved and unresolved issues","volume":"41","author":"Blanchette V","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1111\/jth.14315","article-title":"The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH","volume":"16","author":"Makris M","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"8","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/jth.15397","article-title":"A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH","volume":"19","author":"Galen KPM","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"10","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/jth.14257","article-title":"The predictive value of factor VIII\/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH","volume":"16","author":"Mancuso ME","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"4","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041368","article-title":"Mild and moderate hemophilia A: neglected conditions, still with unmet needs","volume":"12","author":"Castaman G","year":"2023","journal-title":"J Clin Med"},{"issue":"16","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie JM","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.jtha.2024.05.030","article-title":"Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort","volume":"22","author":"Kovel MS","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"6","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"Den Uijl IEM","year":"2011","journal-title":"Haemophilia"},{"issue":"23","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1182\/bloodadvances.2023011366","article-title":"Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A","volume":"7","author":"Agosti P","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"Den Uijl IEM","year":"2011","journal-title":"Haemophilia"},{"issue":"14","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"Kloosterman FR","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100047","article-title":"Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status","volume":"7","author":"Rejt\u0151 J","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/jth.15676","article-title":"Joint status of patients with nonsevere hemophilia A","volume":"20","author":"Zwagemaker AF","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"11","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2023012486","article-title":"Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia","volume":"8","author":"Han JH","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001\u20132018","volume":"19","author":"Hassan S","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"Eckhardt CL","year":"2013","journal-title":"Blood"},{"issue":"6","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2141.2012.09119.x","article-title":"Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands","volume":"157","author":"Eckhardt CL","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1365-2516.2010.02332.x","article-title":"Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma\/albumin\u2010free method] demonstrates efficacy, safety and low\u2010risk for immunogenicity in routine clinical practice","volume":"16","author":"Oldenburg J","year":"2010","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000040966","article-title":"Factor VIII inhibitors in patients with hemophilia A","volume":"102","author":"\u00d6ren H","year":"1999","journal-title":"Acta Haematol"},{"issue":"2","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2516.2011.02629.x","article-title":"Risk of inhibitor development in mild haemophilia A increases with age","volume":"18","author":"Mauser\u2010Bunschoten EP","year":"2012","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.12229","article-title":"Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database","volume":"20","author":"Puetz J","year":"2014","journal-title":"Haemophilia"},{"issue":"04","key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1055\/s-0037-1615061","article-title":"Factor VIII Iinhibitors in mild and moderate\u2010severity haemophilia A","volume":"79","author":"Hay CRM","year":"1998","journal-title":"Thromb Haemost"},{"issue":"1","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-0044-1786358","article-title":"Tank FT. Nonsevere hemophilia: the need for a renewed focus and improved outcomes","volume":"51","author":"Dolan G","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/S2352-3026(23)00270-3","article-title":"Advancements in haemophilia A and health equity: is it time to redefine severity?","volume":"11","author":"Weyand AC","year":"2024","journal-title":"Lancet Haematol"},{"key":"e_1_2_10_40_1","unstructured":"EMA \u2010 Hemlibra. Accessed August 25 2024.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemlibra"},{"key":"e_1_2_10_41_1","unstructured":"FDA \u2010 Hemlibra. Accessed August 25 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761083s018lbl.pdf"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:23:25Z","timestamp":1743377005000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/hem3.70111"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70111","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70111"}}